ArticleFrontiers in oncology2024
Global, regional and national burden of pancreatic cancer and its attributable risk factors from 2019 to 2021, with projection to 2044.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- From radiomics to transformers in pancreatic cancer detection and prognosis.Frontiers in medicine · 2025Pooled it
- Aporphine AlkaloidPharmaceuticals (Basel, Switzerland) · 2026Article
- Current burden, incidence trends, and future projections of pancreatic cancer in adults worldwide.Journal of global health · 2026Article
- Review
- From Physiology to Clinical Practice in Pancreatic Cancer-Related Thromboembolism-A Review.Cancers · 2026Review
- Mismatch Repair Protein and Microsatellite Instability Analysis in Pancreatic Ductal Adenocarcinoma.Journal of clinical medicine · 2026Article
- Invasive Adenosquamous Carcinoma of the Pancreas: Two Case Reports From Tanzania and a Literature Review.Case reports in pathology · 2026Article
- Application of intrahepatic fiducial markers in carbon ion radiotherapy for pancreatic cancer-Achieving higher precision treatment.Journal of applied clinical medical physics · 2026Article
- Conversion and resection rates in borderline resectable and locally advanced pancreatic cancer following neoadjuvant therapy: a retrospective multicenter cohort study.Frontiers in oncology · 2026Article
- Epidemiological Trends and Shared Molecular Signatures of Pancreatic Ductal Adenocarcinoma and Diabetes: An Integrative Analysis Based on Global Burden of Disease and Gene Expression Omnibus Datasets.Journal of Cancer · 2026Article
- Advances in liver and pancreas organoids: how far we have come and where we go next.Nature reviews. Gastroenterology & hepatology · 2026Review
- Peritoneal metastasis in pancreatic cancer: molecular mechanisms, microenvironmental remodeling, and emerging intraperitoneal interventions.Frontiers in molecular biosciences · 2026Review
- Reframing pancreatic cancer diagnosis: metabolic signatures and the challenge of rule-out testing.Translational gastroenterology and hepatology · 2026Article
- Article
- Global disparities in the burden of pancreatic cancer (1990-2021): insights from the 2021 Global Burden of Disease study.BMC cancer · 2025Article
- Lactylation in digestive system tumors: from mechanisms to therapeutic target.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To estimate the global burden of pancreatic cancer in 2019 and 2021 including incidence, mortality, and disability-adjusted-life-years (DALYs). Methods: Data on pancreatic cancer incidence, mortality and DALYs were downloaded from the Global Health Data Exchange. The 95% uncertainty intervals (UIs) were reported for annual numbers and rates (per 100,000 populations). Results: In 2021, there were 508,532 (95% UI: 462,09 to 547,208) incident cases of pancreatic cancer globally, of which 273,617 (250,808 to 299,347; 53.8%) were in males. The age-standardized incidence rate was 6.0 (5.5 to 6.5) per 100,000 people in 2019 and decreased to 5.9 (5.4 to 6.4) per 100,000 people in 2021. There was a 3.9% increase in the number of deaths from pancreatic cancer from 486,869 (446,272 to 517,185) in 2019 to 505,752 (461,224 to 543,899) in 2021. There was a 3.5% increase in DALYs due to pancreatic cancer, increasing from 10.9 million (10.1 to 11.7) in 2019 to 11.3 million (10.5 to 12.2) in 2021. In 2021, the highest age-standardized death rates were observed in Greenland and Monaco, and the highest age-standardized DALY rates were observed in Greenland and Uruguay. The numbers of incident cases and deaths peaked at the ages of 70 to 74 years. The pancreatic cancer burden increased as the socio-demographic index increased. To 2044, the number of incident cases and deaths will be more than 875 thousand and 879 thousand, respectively. Conclusion: The disease burden of pancreatic cancer remains high, especially in high-income regions. More cancer prevention measures are needed in the future to reduce the burden of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.